Rivaroxaban

also known as Xarelto · BAY59-7939 · Rivaroxaban (Xarelto) · Direct Oral Anticoagulant (DOAC) · JNJ39039039 · Rivaroxaban accord · Rivaroxaban viatris (previously rivaroxaban mylan) · Rivaroxabana · +2 more

Other / unclassified targets F10 via inhibition

Developed for: venous thromboembolism · atrial fibrillation · thrombotic disease · coronary artery disorder · peripheral arterial disease · acute coronary syndrome · ischemic stroke · stroke disorder
+76 more
· pulmonary embolism · COVID-19 · ST-elevation myocardial infarction · cancer · antiphospholipid syndrome · cerebral sinovenous thrombosis · cirrhosis of liver · heart failure · intracerebral hemorrhage · myocardial infarction · neoplasm · portal vein thrombosis · cardiac valvular defect · rheumatic heart disease · thrombophlebitis · transient ischemic attack · aortic valve disorder · aortic valve stenosis · arterial occlusion · blood coagulation disease · coronary aneurysm · end stage renal failure · impaired renal function disease · intermediate coronary syndrome · intracranial arteriosclerosis · Kawasaki disease · May-Thurner syndrome · migraine disorder · mitral valve stenosis · plasma cell myeloma · sickle cell disease · vascular ectasia · acquired polycythemia vera · atherosclerosis · atrial flutter · Behcet disease · brain ischemia · cardiac rhythm disease · cardiovascular disorder · carotid stenosis · cerebral atherosclerosis · cerebral infarction · chronic kidney disease · chronic obstructive pulmonary disease · diabetes mellitus, noninsulin-dependent, 2 · esophageal varices with bleeding · essential thrombocythemia · heart valve disorder · heparin-induced thrombocytopenia · hyperheparinemia · hypertrophic cardiomyopathy · idiopathic membranous glomerulonephritis · intermittent vascular claudication · intracranial arterial disease · intracranial embolism · isolated mesenteric vein thrombosis · isolated splenic vein thrombosis · limb ischemia · malignant glioma · malignant urinary system neoplasm · mitral valve insufficiency · osteoporosis · postoperative ventricular dysfunction · primary myelofibrosis · severe acute respiratory syndrome · sickle cell-beta zero-thalassemia · systemic lupus erythematosus · bleeding disorder, vascular-type · calcinosis · coronary atherosclerosis · diabetes mellitus · infective endocarditis · post-thrombotic syndrome · staphylococcal toxemia · staphylococcus aureus infection · traumatic brain injury
Investigated by: Bayer · Janssen Research & Development, LLC · Janssen Scientific Affairs, LLC · Population Health Research Institute · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Assistance Publique - Hôpitaux de Paris
+296 more
· Insel Gruppe AG, University Hospital Bern · Ottawa Hospital Research Institute · Second Affiliated Hospital, School of Medicine, Zhejiang University · National Heart, Lung, and Blood Institute (NHLBI) · Shanghai Zhongshan Hospital · Hamilton Health Sciences Corporation · Radboud University Medical Center · Science Valley Research Institute · Seoul National University Hospital · University Hospital of Saint-Etienne · Asan Medical Center · Canadian Institutes of Health Research (CIHR) · China National Center for Cardiovascular Diseases · Imperial College London · Ottawa Heart Institute Research Corporation · RenJi Hospital · Rigshospitalet, Denmark · The Ottawa Hospital · University Hospital, Angers · University Hospital, Brest · University of Florida · Xijing Hospital · Yonsei University · Aalborg University Hospital · Aarhus University Hospital · Anhui Provincial Hospital · Centre Hospitalier Universitaire Vaudois · Charite University, Berlin, Germany · Children's Hospital of Fudan University · Chinese Academy of Medical Sciences, Fuwai Hospital · GWT-TUD GmbH · Gødstrup Hospital · Heart and Stroke Foundation of Canada · Hospital Universitari Vall d'Hebron Research Institute · Huadong Hospital · Huashan Hospital · Instituto Nacional de Cardiologia Ignacio Chavez · Massachusetts General Hospital · McMaster University · Medical University of Graz · Medical University of South Carolina · Medtronic · Ministry of Health, France · Northwestern University · Odense University Hospital · Onze Lieve Vrouw Hospital · Oslo University Hospital · Queen Elizabeth II Health Sciences Centre · Rajaie Cardiovascular Medical and Research Center · Regeneron Pharmaceuticals · Shanghai 5th People's Hospital · Sir Run Run Shaw Hospital · The First Affiliated Hospital with Nanjing Medical University · University College, London · University of Alberta · University of Cape Town · University of Padova · University of Sao Paulo General Hospital · Vanderbilt University Medical Center · Yantai Yuhuangding Hospital · AHEPA University Hospital · AIO-Studien-gGmbH · AZ Sint-Jan AV · Aalborg University · Abbott · Abidi Pharmaceuticals · Academisch Ziekenhuis Groningen · Action Research Group · Addpharma Inc. · Affiliated Hospital of Jiaxing University · Ahmed AbdelMoneim Hassan Ali · Ain Shams University · Air Force Military Medical University, China · Alexandria University · all 302 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (8)	US (FDA)	XARELTO	—	2012-11-02 – 2021-08-23	fda.gov ↗
Approved	US (FDA)	XARELTO	—	2011-07-01	fda.gov ↗
Approved	EU (EMA)	Xarelto	—	2008-09-30	europa.eu ↗

Trials 281 · started per year

today

EU approved 2008

US approved 2011

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06961630	Oct 2025 → Mar 2027 expected	myocardial infarction	NYU Langone Health	Recruiting	No outcome recorded
Phase 0	NCT07011095	Sep 2025 → Feb 2027 expected	atrial fibrillation	Population Health Research Institute	Not yet recruiting	No outcome recorded
Phase 0	NCT05308030	Aug 2022 → May 2023	peripheral arterial disease	Assiut University	Unknown	No outcome recorded
Phase 0	NCT04994223	Jul 2021 → Dec 2022	peripheral arterial disease	Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi	Unknown	No outcome recorded
Phase 130 trials
Phase 1	NCT06913595	Mar 2024 → Oct 2025 overdue	venous thromboembolism	Cairo University	Active not recruiting	No outcome recorded
Phase 1	NCT06372483	Feb → Aug 2024 overdue	blood coagulation disease	VarmX B.V.	Active not recruiting	No outcome recorded
Phase 1	NCT05723510	Mar → Jul 2023	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT07077954	Jan → Jun 2023	venous thromboembolism	Children Hospital and Institute of Child Health, Lahore	Completed	No outcome recorded
Phase 1	NCT04767776	Jan → Sep 2022	—	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 1	NCT05128591	Nov → Dec 2021	thrombotic disease	Addpharma Inc.	Completed	No outcome recorded
Phase 1	NCT04874428	May 2021 → Jun 2026 overdue	cirrhosis of liver	Insel Gruppe AG, University Hospital Bern	Recruiting	No outcome recorded
Phase 1	NCT05418803	Jan → Feb 2020	—	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT04180436	Jan 2020 → Jun 2022	morbid obesity	University Hospital, Brest	Completed	No outcome recorded
Phase 1	NCT03864406	Jun 2019 → Dec 2022	—	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 1	NCT03796377	Feb → Apr 2019	—	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 1	NCT06065592	Feb 2019 → Dec 2024	breast cancer, colorectal cancer, hepatocellular carcinoma, immune system disorder +4	Lebanese University	Unknown	No outcome recorded
Phase 1	NCT04720092	Jul → Aug 2017	thrombotic disease	Bayer	Completed	No outcome recorded
Phase 1	NCT04727021	Jul → Sep 2017	—	Bayer	Completed	No outcome recorded
Phase 1	NCT02832947	Feb → Jun 2016	venous thromboembolism	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 1	NCT02657512	Jan → Feb 2016	—	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 1	NCT02497716	Nov 2015 → May 2018	thrombotic disease	Bayer	Completed	No outcome recorded
Phase 1	NCT02561923	Aug 2015 → Jun 2016	—	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 1	NCT02438098	Jun → Nov 2015	venous thromboembolism	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 1	NCT02367027	Feb → Apr 2015	—	Bayer	Completed	No outcome recorded
Phase 1	NCT02289703	Jan → Mar 2015	end stage renal failure	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT02058199	Dec 2014 → Dec 2015	—	State University of New York - Upstate Medical University	Terminated	No outcome recorded
Phase 1	NCT01954238	Aug 2013 → Mar 2014	—	Green Cross Corporation	Completed	No outcome recorded
Phase 1	NCT01853800	May → Jul 2013	—	Bayer	Completed	No outcome recorded
Phase 1	NCT01656330	Jul → Aug 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01400646	Oct 2011 → May 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01379300	May → Dec 2011	thrombotic disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01309438	Feb 2011 → Mar 2012	impaired renal function disease	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01145859	Nov 2010 → Jul 2015	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 1	NCT01507051	Nov 2008 → Nov 2009	venous thromboembolism	Bayer	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT03747081	Sep 2018 → Jan 2020	cerebral sinovenous thrombosis	Isfahan University of Medical Sciences	Unknown	No outcome recorded
Phase 1/2	NCT04397289	Feb 2018 → Mar 2021	cirrhosis of liver, hemorrhagic disease, portal hypertension, thrombotic disease	First Affiliated Hospital Xi'an Jiaotong University	Completed	No outcome recorded
Phase 1/2	NCT03282643	Feb 2016 → Jun 2018	neoplasm	Capital Medical University	Completed	No outcome recorded
Phase 1/2	NCT02564718	Nov 2015 → Dec 2017	thrombotic disease	Bayer	Completed	No outcome recorded
Phase 234 trials
Phase 2	NCT07246005	Dec 2026 → Dec 2027 expected	thrombotic disease	Queen Mary University of London	Not yet recruiting	No outcome recorded
Phase 2	NCT05775965	May 2024 → Mar 2025 overdue	osteoporosis	University of Calgary	Recruiting	No outcome recorded
Phase 2	NCT05546320	Oct 2022 → Mar 2025	migraine disorder, patent foramen ovale	Chinese Academy of Medical Sciences, Fuwai Hospital	Completed	No outcome recorded
Phase 2	NCT05006287	Oct 2022 → May 2024	atrial fibrillation	St. Paul's Hospital, Canada	Unknown	No outcome recorded
Phase 2	NCT05033964	Dec 2021 → Dec 2022 overdue	coronary artery disorder	Elixir Medical Corporation	Active not recruiting	No outcome recorded
Phase 2	NCT05233124	Sep 2021 → Jun 2023	acute coronary syndrome, vascular ectasia	Instituto Nacional de Cardiologia Ignacio Chavez	Unknown	No outcome recorded
Phase 2	NCT03684564	Jul 2021 → Jul 2025	antiphospholipid syndrome, brain ischemia, ischemic stroke, systemic lupus erythematosus	University College, London	Completed	No outcome recorded
Phase 2	NCT04416048	Nov 2020 → Jul 2021	COVID-19	Charite University, Berlin, Germany	Terminated	No outcome recorded
Phase 2	NCT04504032	Sep 2020 → Mar 2021	COVID-19	Gates Medical Research Institute	Terminated	No outcome recorded
Phase 2	NCT03178864	Mar 2019 → Oct 2022	cerebral sinovenous thrombosis	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT03310021	Aug 2017 → Aug 2019	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03139487	Aug 2017 → Sep 2021	ampulla of vater cancer, esophageal cancer, gastric cancer, gastroesophageal cancer +3	Asan Medical Center	Unknown	No outcome recorded
Phase 2	NCT02998905	Apr 2017 → Oct 2019	atrial fibrillation, intracerebral hemorrhage	Population Health Research Institute	Completed	No outcome recorded
Phase 2	NCT02293395	Apr 2015 → Oct 2016	acute coronary syndrome	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT02309411	Jan 2015 → Apr 2017	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT02271399	Oct 2014 → Jan 2016	venous thromboembolism	Hanyang University Seoul Hospital	Completed	No outcome recorded
Phase 2	NCT02260622	Oct 2014 → Jun 2017	limb ischemia	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 2	NCT02072668	Feb 2014 → Oct 2018	sickle cell disease, sickle cell-beta zero-thalassemia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT02042534	Jan 2014 → Dec 2015	transient ischemic attack	Asan Medical Center	Completed	No outcome recorded
Phase 2	NCT01684423	Feb 2013 → Sep 2016	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT02128841	Sep 2012 → Sep 2017	aortic valve disorder, cardiac valvular defect	Insel Gruppe AG, University Hospital Bern	Terminated	No outcome recorded
Phase 2	NCT01629381	May 2012 → Mar 2014	hemorrhagic disease, venous thromboembolism	University of Padova	Completed	No outcome recorded
Phase 2	NCT01442792	Oct 2011 → Jan 2013	coronary artery disorder	Bayer	Completed	No outcome recorded
Phase 2	NCT00786422	May 2009 → May 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00402597	Nov 2006 → Oct 2008	acute coronary syndrome	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 2	NCT00973245	Jul 2006 → Jan 2007	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT00973323	Sep 2005 → Mar 2006	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT00395772	Dec 2004 → Dec 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00396786	Nov 2004 → Jul 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00779064	Jul 2004 → Jun 2005	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT00839163	Mar 2004 → Oct 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00402467	Feb → Nov 2004	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00398905	Jan → Sep 2004	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00839826	Dec 2002 → Nov 2003	venous thromboembolism	Bayer	Completed	No outcome recorded

Phase 2/38 trials
Phase 2/3	NCT06965998	Aug 2025 → Aug 2026 overdue	thrombophlebitis, thrombotic disease	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 2/3	NCT05920343	Nov 2024 → Oct 2026 expected	malignant urinary system neoplasm, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 2/3	NCT05700266	Dec 2023 → Dec 2024	intracranial arteriosclerosis, ischemic stroke	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded
Phase 2/3	NCT04273516	Aug 2020 → Apr 2023	ischemic stroke	Mazandaran University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT04351724	Apr 2020 → Dec 2021	COVID-19	Medical University of Vienna	Unknown	No outcome recorded
Phase 2/3	NCT03428373	Jan 2019 → Dec 2023	plasma cell myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	No outcome recorded
Phase 2/3	NCT03273322	Sep 2017 → Nov 2018	atrial fibrillation, hemorrhagic disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2/3	NCT01923818	Sep 2013 → Sep 2015	transient ischemic attack	Xijing Hospital	Unknown	No outcome recorded
Phase 397 trials
Phase 3	NCT07318610	Jul 2026 → Aug 2029 expected	peripheral arterial disease	Regeneron Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT07468448	May 2026 → Dec 2029 expected	cerebral atherosclerosis, ischemic stroke	Population Health Research Institute	Not yet recruiting	No outcome recorded
Phase 3	NCT07202897	Jan 2026 → Jan 2032 expected	hypertrophic cardiomyopathy	Rennes University Hospital	Recruiting	No outcome recorded
Phase 3	NCT07456085	Nov 2025 → Apr 2027 expected	heart valve disorder	Rawalpindi Institute of Cardiology	Enrolling by invitation	No outcome recorded
Phase 3	NCT06580223	Sep 2025 → Sep 2027 expected	plasma cell myeloma, venous thromboembolism	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Not yet recruiting	No outcome recorded
Phase 3	NCT06780462	Jun 2025 → Dec 2027 expected	Behcet disease	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05410275	Jan 2025 → Jan 2027 expected	chronic kidney disease	University Hospital, Tours	Recruiting	No outcome recorded
Phase 3	NCT06611319	Nov 2024 → Mar 2027 expected	osteoarthritis, hip, venous thromboembolism	Prof. Stavros Konstantinides, MD	Recruiting	No outcome recorded
Phase 3	NCT06195540	Jul 2024 → Nov 2028 expected	pulmonary embolism, venous thromboembolism	University Hospital, Angers	Recruiting	No outcome recorded
Phase 3	NCT05387954	Jul 2023 → Jul 2031 expected	ischemic stroke, patent foramen ovale	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05825573	May 2023 → Feb 2025 overdue	ST-elevation myocardial infarction, heart failure, thrombotic disease	Nîmes University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT05029063	Oct 2022 → Dec 2026 expected	cancer, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 3	NCT05047172	Aug 2022 → Jan 2027 expected	intracranial arteriosclerosis, stroke disorder	University of Florida	Active not recruiting	No outcome recorded
Phase 3	NCT05198960	Jul 2022 → Jul 2027 expected	acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis	University Hospital, Brest	Recruiting	No outcome recorded
Phase 3	NCT05033314	Jun 2022 → Oct 2024	sickle cell disease, venous thromboembolism	University Health Network, Toronto	Terminated	No outcome recorded
Phase 3	NCT02832531	Jan → Apr 2022	rheumatic heart disease	Population Health Research Institute	Withdrawn	No outcome recorded
Phase 3	NCT05035277	Dec 2021 → Jun 2026	aortic valve stenosis	Oslo University Hospital	Completed	No outcome recorded
Phase 3	NCT05077683	Oct 2021 → Mar 2023	acute myocardial infarction, thrombotic disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT04967573	Aug 2021 → Jun 2023	venous thromboembolism	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
Phase 3	NCT03969953	Jan 2021 → Oct 2025	cardiovascular disorder, end stage renal failure	The George Institute	Completed	No outcome recorded
Phase 3	NCT04999176	Oct 2020 → Jul 2024	cancer, venous thromboembolism	André Luiz Malavasi Longo de Oliveira	Unknown	No outcome recorded
Phase 3	NCT04662684	Oct 2020 → Jul 2021	COVID-19, venous thromboembolism	Science Valley Research Institute	Completed	No outcome recorded
Phase 3	NCT04508023	Aug 2020 → Jun 2022	COVID-19	Janssen Research & Development, LLC	Terminated	No outcome recorded
Phase 3	NCT05705089	Jul 2020 → Feb 2023	ST-elevation myocardial infarction, thrombotic disease	Rajaie Cardiovascular Medical and Research Center	Completed	No outcome recorded
Phase 3	NCT04067505	May 2020 → Dec 2024	May-Thurner syndrome	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 3	NCT04066764	May 2020 → Oct 2024	venous thromboembolism	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 3	NCT04324463	Apr 2020 → Dec 2022	severe acute respiratory syndrome	Population Health Research Institute	Completed	No outcome recorded
Phase 3	NCT04309240	Mar 2020 → Mar 2022	cancer, venous thromboembolism	LiuZhou People's Hospital	Unknown	No outcome recorded
Phase 3	NCT04142125	Feb 2020 → Sep 2023	intracranial arterial disease, ischemic stroke	Population Health Research Institute	Completed	No outcome recorded
Phase 3	NCT03764241	Feb 2020 → Mar 2022	ST-elevation myocardial infarction, thrombotic disease	RenJi Hospital	Unknown	No outcome recorded
Phase 3	NCT04045665	Dec 2019 → Aug 2026 overdue	atrial fibrillation, hemorrhagic disease, stroke disorder	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 3	NCT03996772	Jun 2019 → May 2024	atrial fibrillation, intracerebral hemorrhage	Imperial College London	Completed	No outcome recorded
Phase 3	NCT03926156	May 2019 → May 2021	atrial fibrillation, mitral valve stenosis, rheumatic heart disease	Rajaie Cardiovascular Medical and Research Center	Terminated	No outcome recorded
Phase 3	NCT03702582	Apr 2019 → Oct 2023	atrial fibrillation, hemorrhagic disease, stroke disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT03786757	Apr 2019 → Mar 2022	ST-elevation myocardial infarction, thrombotic disease	RenJi Hospital	Unknown	No outcome recorded
Phase 3	NCT03506815	Mar 2019 → May 2020	cancer, venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 3	NCT03926780	Dec 2018 → May 2020	hyperheparinemia, thrombotic disease	The Young Investigator Group of Cardiovascular Research	Completed	No outcome recorded
Phase 3	NCT03605433	Dec 2018 → Dec 2019	coronary artery disorder	Unidade Local de Saúde de Coimbra, EPE	Unknown	No outcome recorded
Phase 3	NCT03331484	Nov 2018 → Jul 2023	acute coronary syndrome, atrial fibrillation	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT03630055	Oct 2018 → Jun 2025	arterial occlusion	Ottawa Heart Institute Research Corporation	Terminated	No outcome recorded
Phase 3	NCT03153150	Mar 2018 → Mar 2021	atrial fibrillation, atrial flutter, intracerebral hemorrhage, subarachnoid hemorrhage	University of Edinburgh	Completed	No outcome recorded
Phase 3	NCT03285438	Nov 2017 → Nov 2023	venous thromboembolism	University Hospital, Brest	Completed	No outcome recorded
Phase 3	NCT04569279	Sep 2017 → Mar 2020	cerebral sinovenous thrombosis	Damascus University	Completed	No outcome recorded
Phase 3	NCT03055026	May 2017 → Jul 2021	venous thromboembolism	Fadoi Foundation, Italy	Completed	No outcome recorded
Phase 3	NCT03181386	May 2017 → Nov 2020	atrial fibrillation, hemorrhagic disease, periodontal disorder	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 3	NCT03299296	Jan 2017 → Jan 2018	venous thromboembolism	Ahmed AbdelMoneim Hassan Ali	Unknown	No outcome recorded
Phase 3	NCT02846532	Nov 2016 → Jul 2020	thrombotic disease	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02664155	Oct 2016 → Nov 2021	impaired renal function disease	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 3	NCT02746185	Sep 2016 → Apr 2018	neoplasm, venous thromboembolism	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02832544	Aug 2016 → Aug 2022	rheumatic heart disease	Population Health Research Institute	Completed	No outcome recorded
Phase 3	NCT02643212	May 2016 → Dec 2019	cirrhosis of liver	David Garcia Cinca	Unknown	No outcome recorded
Phase 3	NCT02833948	May 2016 → Dec 2018	aortic valve stenosis, cardiac valvular defect, thrombotic disease	ECRI bv	Completed	No outcome recorded
Phase 3	NCT02583191	Mar 2016 → Jun 2019	cancer, venous thromboembolism	AIO-Studien-gGmbH	Terminated	No outcome recorded
Phase 3	NCT02556203	Dec 2015 → Nov 2018	—	Bayer	Terminated	No outcome recorded
Phase 3	NCT02401594	Dec 2015 → Apr 2018	—	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 3	NCT02627053	Dec 2015 → Jun 2019	isolated mesenteric vein thrombosis, isolated splenic vein thrombosis, portal vein thrombosis	University of Insubria	Unknown	No outcome recorded
Phase 3	NCT02544932	Oct 2015 → Sep 2017	atrial fibrillation	Kyunghee University Medical Center	Unknown	No outcome recorded
Phase 3	NCT02555878	Sep 2015 → Aug 2018	neoplasm	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02555111	Sep 2015 → Feb 2020	portal vein thrombosis, venous thromboembolism	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02504216	Aug 2015 → Nov 2019	peripheral arterial disease	Bayer	Completed	No outcome recorded
Phase 3	NCT02164578	Apr 2015 → Dec 2018	diabetes mellitus, noninsulin-dependent, 2	GWT-TUD GmbH	Completed	No outcome recorded
Phase 3	NCT02486445	Mar 2015 → Nov 2018	venous thromboembolism	Ostfold Hospital Trust	Completed	No outcome recorded
Phase 3	NCT02313909	Dec 2014 → Feb 2018	stroke disorder	Bayer	Terminated	No outcome recorded
Phase 3	NCT02157272	Dec 2014 → Jan 2018	antiphospholipid syndrome	University of Padova	Terminated	No outcome recorded
Phase 3	NCT02234843	Nov 2014 → Jan 2019	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT02123524	Nov 2014 → Dec 2018	thrombophlebitis	McMaster University	Completed	No outcome recorded
Phase 3	NCT03193502	May 2014 → Jul 2020	portal vein thrombosis	Tanta University	Unknown	No outcome recorded
Phase 3	NCT02064439	Mar 2014 → Sep 2016	pulmonary embolism, venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT02111564	Jan 2014 → Mar 2018	heart failure, infectious disease, respiratory failure, rheumatic disorder +1	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT01877915	Sep 2013 → Apr 2018	coronary artery disorder, heart failure	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT01839357	Aug 2013 → Nov 2014	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 3	NCT01830543	May 2013 → Jul 2016	atrial fibrillation	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT02926170	Mar 2013 → Dec 2017	antiphospholipid syndrome	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
Phase 3	NCT01776424	Feb 2013 → Jul 2017	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01720108	Feb 2013 → Jul 2016	venous thromboembolism	David Anderson	Completed	No outcome recorded
Phase 3	NCT01729871	Feb 2013 → Oct 2014	atrial fibrillation	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT01675076	Jan 2013 → Oct 2017	—	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT01598168	Jan 2013 → Jul 2015	heparin-induced thrombocytopenia	McMaster University	Terminated	No outcome recorded
Phase 3	NCT01674647	Oct 2012 → Jan 2014	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 3	NCT01499953	Apr 2012 → May 2016	thrombophlebitis	GWT-TUD GmbH	Completed	No outcome recorded
Phase 3	NCT01516840	Mar 2012 → Dec 2013	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01516814	Feb 2012 → Oct 2013	pulmonary embolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01206972	Oct 2010 → May 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01205932	Sep 2010 → Jun 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01094886	Mar → Dec 2010	osteoarthritis, hip, osteoarthritis, knee, venous thromboembolism	Ortho-McNeil Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT00809965	Nov 2008 → Sep 2011	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00562289	Dec 2007 → Dec 2016	atrial septal aneurysm, ischemic stroke, migraine disorder, patent foramen ovale	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00571649	Dec 2007 → Aug 2010	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00494871	Jun 2007 → Dec 2009	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 3	NCT00439777	Mar 2007 → Sep 2011	pulmonary embolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00440193	Mar 2007 → Apr 2010	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00439725	Feb 2007 → Aug 2009	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00403767	Dec 2006 → Sep 2010	atrial fibrillation, stroke disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00362232	Jun 2006 → Jan 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00361894	Feb 2006 → Jan 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00329628	Feb 2006 → Mar 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00332020	Feb 2006 → May 2007	venous thromboembolism	Bayer	Completed	No outcome recorded

Phase 472 trials
Phase 4	NCT07609654	Jun 2026 → Jun 2029 expected	atrial fibrillation, intracerebral hemorrhage, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 4	NCT07511257	Feb 2026 → Jun 2029 expected	ST-elevation myocardial infarction, acute coronary syndrome, vascular ectasia	Instituto Nacional de Cardiologia Ignacio Chavez	Recruiting	No outcome recorded
Phase 4	NCT07195812	Oct 2025 → May 2028 expected	ST-elevation myocardial infarction	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 4	NCT06901466	Jun 2025 → Oct 2027 expected	mitral valve insufficiency	Chinese Academy of Medical Sciences, Fuwai Hospital	Recruiting	No outcome recorded
Phase 4	NCT05643651	Jun 2025 → Jun 2027 expected	Kawasaki disease, coronary aneurysm	Children's Hospital of Fudan University	Recruiting	No outcome recorded
Phase 4	NCT06812455	Mar 2025 → Mar 2028 expected	arterial occlusion	AHEPA University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06108414	Sep 2024 → Dec 2026 expected	atrial fibrillation, stroke disorder	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 4	NCT07618988	Aug 2024 → Dec 2025	venous thromboembolism	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT06476301	Aug 2024 → Feb 2026 overdue	—	RenJi Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06401616	May 2024 → Mar 2028 expected	atrial fibrillation	Odense University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06013020	Apr 2024 → Dec 2026 expected	ST-elevation myocardial infarction	Zunyi Medical College	Recruiting	No outcome recorded
Phase 4	NCT06873321	Feb 2024 → Jul 2025 overdue	peripheral arterial disease, venous thromboembolism	Science Valley Research Institute	Recruiting	No outcome recorded
Phase 4	NCT05735639	Jan 2024 → Jun 2027 expected	varicose disease, venous thromboembolism	Imperial College London	Recruiting	No outcome recorded
Phase 4	NCT06978439	Jan 2024 → Dec 2025 overdue	Kawasaki disease, coronary aneurysm	Children's Hospital of Fudan University	Recruiting	No outcome recorded
Phase 4	NCT07404436	Jan 2024 → Dec 2026 expected	idiopathic membranous glomerulonephritis	Beijing Friendship Hospital	Recruiting	No outcome recorded
Phase 4	NCT06103266	Jan 2024 → Jun 2025	atrial fibrillation, coronary artery disorder	J.P.S Henriques	Unknown	No outcome recorded
Phase 4	NCT05638867	Nov 2023 → Dec 2026 expected	acute coronary syndrome, coronary artery disorder	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 4	NCT06314763	Nov 2023 → Mar 2024	—	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT05794399	Jun 2023 → Mar 2026 overdue	myocardial infarction, thrombotic disease	Shahid Gangalal National Heart Centre	Recruiting	No outcome recorded
Phase 4	NCT05973188	May 2023 → Jun 2024	thrombotic disease	Peshawar Institute of Cardiology	Unknown	No outcome recorded
Phase 4	NCT05487950	Apr 2023 → Apr 2027 expected	cardiac rhythm disease	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 4	NCT06187311	Jan 2023 → Jun 2026 overdue	atrial fibrillation	Korea University Anam Hospital	Recruiting	No outcome recorded
Phase 4	NCT04135677	Nov 2022 → Oct 2024	stroke disorder, thrombotic disease	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
Phase 4	NCT05573958	Oct 2022 → Mar 2023	acute coronary syndrome	Sarmad Zahoor	Unknown	No outcome recorded
Phase 4	NCT05303818	Jun 2022 → Jun 2023	colorectal cancer, venous thromboembolism	Hospital do Servidor Publico Estadual	Unknown	No outcome recorded
Phase 4	NCT05009862	Apr 2022 → Jul 2025	peripheral arterial disease	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT05210725	Mar → Apr 2022	coronary artery disorder	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT04258488	Feb 2022 → Dec 2027 expected	aortic valve disorder, thrombotic disease	Joon Bum Kim	Recruiting	No outcome recorded
Phase 4	NCT05671276	Feb 2022 → Sep 2024	atrial fibrillation, intracranial embolism	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded
Phase 4	NCT05292846	Jan 2022 → Feb 2024	coronary artery disorder, hemorrhagic disease	Hospital Universitario La Fe	Unknown	No outcome recorded
Phase 4	NCT04990791	Aug 2021 → Aug 2023	coronary artery disorder	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT05797376	Aug 2021 → Nov 2024	atherosclerosis, carotid stenosis, coronary artery disorder, peripheral arterial disease	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT04970576	Jun 2021 → May 2024	acute coronary syndrome, thrombotic disease	National Institute of Cardiovascular Diseases, Pakistan	Completed	No outcome recorded
Phase 4	NCT04700826	Jun 2021 → Dec 2027 expected	atrial fibrillation	University of Birmingham	Recruiting	No outcome recorded
Phase 4	NCT04853719	Apr 2021 → Nov 2022	intermittent vascular claudication, peripheral arterial disease	Science Valley Research Institute	Completed	No outcome recorded
Phase 4	NCT04805710	Mar 2021 → Sep 2022	—	Shenyang Northern Hospital	Unknown	No outcome recorded
Phase 4	NCT04619927	Mar 2021 → Jun 2024	peripheral arterial disease	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT06019741	Feb 2021 → May 2022	postoperative ventricular dysfunction	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT05300555	Jan 2021 → Jan 2022	atrial fibrillation	University of Sao Paulo General Hospital	Unknown	No outcome recorded
Phase 4	NCT04715295	Oct 2020 → May 2021	COVID-19	Yaounde Central Hospital	Unknown	No outcome recorded
Phase 4	NCT04437654	Jul 2020 → Aug 2025	—	Yonsei University	Completed	No outcome recorded
Phase 4	NCT04394377	Jun 2020 → Mar 2021	COVID-19	Brazilian Clinical Research Institute	Completed	No outcome recorded
Phase 4	NCT04218656	Jun 2020 → Dec 2021	peripheral arterial disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT04256525	May 2020 → Aug 2021	venous thromboembolism	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT04073316	Feb 2020 → Feb 2023	atrial fibrillation	University Hospital, Angers	Unknown	No outcome recorded
Phase 4	NCT04059679	Jan 2020 → Mar 2021	coronary artery disorder, peripheral arterial disease	LifeBridge Health	Unknown	No outcome recorded
Phase 4	NCT04006288	Sep 2019 → Jan 2022	coronary artery disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT03968393	Jun 2019 → Dec 2028 expected	atrial fibrillation, stroke disorder	Population Health Research Institute	Recruiting	No outcome recorded
Phase 4	NCT03718429	Jan 2019 → Feb 2020	atrial fibrillation, coronary artery disorder, peripheral arterial disease	University of Florida	Completed	No outcome recorded
Phase 4	NCT03775746	Jan 2019 → Dec 2021	acute coronary syndrome	East and North Hertfordshire NHS Trust	Unknown	No outcome recorded
Phase 4	NCT03749057	Nov 2018 → Mar 2025	cerebral infarction, transient ischemic attack	General Hospital of Shenyang Military Region	Completed	No outcome recorded
Phase 4	NCT03490994	Apr 2018 → Sep 2019	heart failure	Yonsei University	Unknown	No outcome recorded
Phase 4	NCT07699796	Mar 2018 → Nov 2020	chronic venous insufficiency, varicose disease, venous thromboembolism	Heart, Artery, and Vein Center of Fresno	Completed	No outcome recorded
Phase 4	NCT03363035	Jan 2018 → Nov 2021	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	Second Xiangya Hospital of Central South University	Completed	No outcome recorded
Phase 4	NCT02970773	Dec 2017 → Dec 2018	spinal cord injury, thrombotic disease	Swiss Paraplegic Research, Nottwil	Withdrawn	No outcome recorded
Phase 4	NCT03799822	May 2017 → Sep 2020	atrial fibrillation	Onze Lieve Vrouw Hospital	Completed	No outcome recorded
Phase 4	NCT02666742	Feb 2017 → May 2020	stroke disorder, ventricular tachycardia	Kansas City Heart Rhythm Institute	Completed	No outcome recorded
Phase 4	NCT03673605	Dec 2016 → Oct 2017	atrial fibrillation, mitral valve stenosis	PharmEvo Pvt Ltd	Withdrawn	No outcome recorded
Phase 4	NCT02810704	Dec 2016 → Sep 2025	pulmonary embolism, venous thromboembolism	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 4	NCT02584660	Oct 2015 → Mar 2017	pulmonary embolism	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 4	NCT02426944	Oct 2015 → Jul 2019	atrial fibrillation	Charles University, Czech Republic	Completed	No outcome recorded
Phase 4	NCT02506985	Jul 2015 → Jun 2016	pulmonary embolism, venous thromboembolism	Susan Smyth	Terminated	No outcome recorded
Phase 4	NCT02642419	Jan 2015 → Dec 2017	atrial fibrillation	Japan Cardiovascular Research Foundation	Unknown	No outcome recorded
Phase 4	NCT02116036	Sep 2014 → Sep 2017	antiphospholipid syndrome	St. Joseph's Healthcare Hamilton	Completed	No outcome recorded
Phase 4	NCT01989845	Oct 2013 → Dec 2016	blood coagulation disease, hemorrhagic disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 4	NCT02047006	Sep 2013 → Feb 2014	chronic renal failure syndrome	AZ Sint-Jan AV	Completed	No outcome recorded
Phase 4	NCT02334254	Aug 2013 → Jan 2016	atrial fibrillation	Beijing Anzhen Hospital	Unknown	No outcome recorded
Phase 4	NCT02066662	Jul 2013 → Mar 2020	arterial disorder	RWTH Aachen University	Completed	No outcome recorded
Phase 4	NCT02161965	May 2013 → Dec 2016	atrial fibrillation, pulmonary embolism, venous thromboembolism	University Hospital, Angers	Completed	No outcome recorded
Phase 4	NCT01708850	Nov 2012 → May 2016	neoplasm, venous thromboembolism	London Health Sciences Centre	Completed	No outcome recorded
Phase 4	NCT01706146	Oct 2012 → Feb 2015	atrial fibrillation	Northwestern University	Completed	No outcome recorded
Phase 4	NCT01210755	Nov 2010 → Mar 2011	venous thromboembolism	University Hospital, Grenoble	Completed	No outcome recorded

Phase not applicable31 trials
—	NCT07583784	Jul 2026 → Dec 2031 expected	ST-elevation myocardial infarction, atrial fibrillation	Chonnam National University Hospital	Not yet recruiting	No outcome recorded
—	NCT07602062	Jun 2026 → Dec 2027 expected	esophageal varices with bleeding, portal vein thrombosis	Shanghai Zhongshan Hospital	Not yet recruiting	No outcome recorded
—	NCT07613840	Apr 2025 → Apr 2027 expected	peripheral arterial disease, thrombotic disease	Massachusetts General Hospital	Recruiting	No outcome recorded
—	NCT07270263	Nov 2024 → Apr 2026 overdue	leukemia, lymphoma, pulmonary embolism, venous thromboembolism	Medical University of Gdansk	Recruiting	No outcome recorded
—	NCT06689241	Oct 2024 → Dec 2025 overdue	morbid obesity	Alexandria University	Recruiting	No outcome recorded
—	NCT06216769	Feb 2024 → Dec 2030 expected	atrial fibrillation	Seoul National University Hospital	Recruiting	No outcome recorded
—	NCT07523347	Dec 2023 → Dec 2025	cerebral sinovenous thrombosis	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT06196918	Nov 2023 → Aug 2024	malignant glioma	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
—	NCT06057467	Sep 2023 → Oct 2025	atrial fibrillation, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
—	NCT05960721	Jul 2023 → Jul 2025 overdue	atrial fibrillation	Xijing Hospital	Recruiting	No outcome recorded
—	NCT05892042	May 2023 → Sep 2026 expected	ST-elevation myocardial infarction, thrombotic disease	Jilin University	Recruiting	No outcome recorded
—	NCT05750758	Feb → Aug 2023	acute coronary syndrome	Henan Institute of Cardiovascular Epidemiology	Completed	No outcome recorded
—	NCT05449327	Feb 2023 → Sep 2025	venous thromboembolism	Chiayi Christian Hospital	Completed	No outcome recorded
—	NCT05546957	Jan → Apr 2023	—	Regeneron Pharmaceuticals	Completed	No outcome recorded
—	NCT05353140	Sep 2022 → Sep 2028 expected	atrial fibrillation	Xijing Hospital	Recruiting	No outcome recorded
—	NCT04694248	Nov 2021 → Dec 2026 expected	May-Thurner syndrome, iliac vein thrombophlebitis, venous thromboembolism	First Affiliated Hospital of Zhejiang University	Recruiting	No outcome recorded
—	NCT04935515	Apr → May 2021	COVID-19	Manimarane Arjunan, MD,DM (Cardiology)	Completed	No outcome recorded
—	NCT04486859	Dec 2020 → May 2025 overdue	Cushing disease due to pituitary adenoma, pulmonary embolism, venous thromboembolism	Huashan Hospital	Active not recruiting	No outcome recorded
—	NCT04970381	Sep 2020 → Oct 2022	thrombotic disease	China National Center for Cardiovascular Diseases	Completed	No outcome recorded
—	NCT05801068	Aug 2020 → May 2024 overdue	atrial fibrillation, hemorrhagic disease	Seoul National University Hospital	Active not recruiting	No outcome recorded
—	NCT04333407	Apr 2020 → Nov 2021	COVID-19	Imperial College London	Terminated	No outcome recorded
—	NCT03759938	Jun 2019 → May 2024	atrial fibrillation, ischemic stroke	University College, London	Unknown	No outcome recorded
—	NCT03792152	Jun 2019 → Jan 2022	atrial fibrillation	The Second Affiliated Hospital of Chongqing Medical University	Unknown	No outcome recorded
—	NCT03642509	Jan 2019 → Jan 2026 overdue	atrial fibrillation, stroke disorder	University of Aarhus	Recruiting	No outcome recorded
—	NCT03148457	Nov 2017 → Dec 2022	ischemic stroke	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
—	NCT03277001	Oct 2017 → Jul 2019	chronic obstructive pulmonary disease, venous thromboembolism	Huashan Hospital	Unknown	No outcome recorded
—	NCT03005444	Jun 2017 → Dec 2023	cirrhosis of liver	Air Force Military Medical University, China	Unknown	No outcome recorded
—	NCT03804697	Aug 2016 → Aug 2017	venous thromboembolism	Guangdong Provincial People's Hospital	Completed	No outcome recorded
—	NCT02504177	Jun 2015 → Jun 2019	atrial fibrillation	Yonsei University	Unknown	No outcome recorded
—	NCT01986192	Nov 2013 → Feb 2015	venous thromboembolism	Seoul National University Hospital	Unknown	No outcome recorded
—	NCT02085824	Jul 2012 → Apr 2014	osteoarthritis, hip	Centre of Postgraduate Medical Education	Unknown	No outcome recorded

Phase not stated1 trial
—	NCT02894307	—	cardiac valvular defect	Hospital Ana Nery	No longer available	No outcome recorded

Also used as a comparator or background therapy in 110 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06615596 Comparator	Aug 2025 → Jan 2029 expected	atrial fibrillation	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 0	NCT07032025 Comparator	Jul 2025 → Jul 2027 expected	pulmonary embolism	RenJi Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT06145269 Comparator	Dec 2023 → Apr 2025	venous thromboembolism	Assiut University	Unknown	No outcome recorded
Phase 0	NCT02331095 Background	Jan 2015 → Oct 2017	venous thromboembolism	Ohio State University	Terminated	No outcome recorded
Phase 18 trials
Phase 1	NCT07312851 Background	Jan → Jun 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06831474 Comparator	Jul 2025 → Apr 2026 overdue	puerperal disorder, venous thromboembolism	Thomas Jefferson University	Recruiting	No outcome recorded
Phase 1	NCT06444178 Comparator	Sep 2024 → Apr 2025	—	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT06517563 Background	Aug → Dec 2024	blood coagulation disease	VarmX B.V.	Completed	No outcome recorded
Phase 1	NCT05491460 Comparator	Jul 2022 → Dec 2023	—	Doasense GmbH	Unknown	No outcome recorded
Phase 1	NCT05152420 Background	Oct 2021 → Feb 2023	blood coagulation disease	VarmX B.V.	Completed	No outcome recorded
Phase 1	NCT03083704 Background	Feb → Sep 2017	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01464450 Comparator	Oct → Dec 2011	—	Janssen Scientific Affairs, LLC	Completed	No outcome recorded

Phase 211 trials
Phase 2	NCT06220123 Comparator	Feb → Dec 2024	—	Beijing Suncadia Pharmaceuticals Co., Ltd	Completed	No outcome recorded
Phase 2	NCT05498428 Background	Nov 2022 → Aug 2027 expected	non-small cell lung carcinoma	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 2	NCT04002011 Comparator	Mar 2022 → Jan 2023	bleeding disorder, vascular-type	Laval University	Withdrawn	No outcome recorded
Phase 2	NCT05088928 Comparator	Mar → May 2022	COVID-19	Scotmann Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT04755283 Comparator	Feb 2021 → Feb 2024 overdue	atrial fibrillation, stroke disorder	Anthos Therapeutics, Inc.	Active not recruiting	No outcome recorded
Phase 2	NCT04640181 Comparator	Dec 2020 → Jun 2021	COVID-19	St. David's HealthCare	Completed	No outcome recorded
Phase 2	NCT03522259 Comparator	Jul 2018 → Dec 2023	—	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 2	NCT03172910 Background	May 2017 → Nov 2019	—	AMAG Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02303795 Comparator	Aug 2015 → Aug 2020	heart valve disorder	Hospital do Coracao	Completed	No outcome recorded
Phase 2	NCT03578146 Background	Dec 2012 → Sep 2015	—	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01344954 Comparator	Apr → Dec 2011	venous thromboembolism	ThromboGenics	Completed	No outcome recorded

Phase 2/35 trials
Phase 2/3	NCT04838808 Comparator	Apr 2021 → May 2022	myocardial infarction	University of Alberta	Completed	No outcome recorded
Phase 2/3	NCT05515120 Comparator	Jan 2021 → Jan 2022	bleeding disorder, vascular-type, pulmonary embolism, venous thromboembolism	Mexican Social Security Institute	Completed	No outcome recorded
Phase 2/3	NCT03566303 Comparator	Jul 2018 → Apr 2020	blood coagulation disease, heart valve disorder, stroke disorder	Hospital Geral Roberto Santos	Terminated	No outcome recorded
Phase 2/3	NCT02829957 Comparator	Sep 2016 → Feb 2020	menstrual disorder, venous thromboembolism	Indiana University	Completed	No outcome recorded
Phase 2/3	NCT01627665 Comparator	Oct 2011 → Jun 2014	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 314 trials
Phase 3	NCT07228663 Comparator	Dec 2025 → Jul 2027 expected	venous thromboembolism	McMaster University	Not yet recruiting	No outcome recorded
Phase 3	NCT06925698 Comparator	Apr 2025 → Apr 2027 expected	Behcet disease, post-thrombotic syndrome, venous thromboembolism	Marmara University	Not yet recruiting	No outcome recorded
Phase 3	NCT06322953 Comparator	Mar 2025 → Dec 2027 expected	traumatic brain injury	Walton Centre NHS Foundation Trust	Recruiting	No outcome recorded
Phase 3	NCT06370273 Comparator	Nov 2024 → Aug 2028 expected	thrombotic disease	Queen Mary University of London	Recruiting	No outcome recorded
Phase 3	NCT06551402 Comparator	Aug 2024 → Oct 2026 expected	cerebral sinovenous thrombosis	Kafrelsheikh University	Recruiting	No outcome recorded
Phase 3	NCT05718531 Comparator	Feb 2023 → Feb 2025	vascular ectasia	Assiut University	Unknown	No outcome recorded
Phase 3	NCT06531122 Comparator	Aug 2021 → Sep 2024 overdue	cerebral sinovenous thrombosis	Kafrelsheikh University	Recruiting	No outcome recorded
Phase 3	NCT04284839 Comparator	Jul 2021 → Jun 2027 expected	—	Population Health Research Institute	Recruiting	No outcome recorded
Phase 3	NCT04075240 Comparator	Feb 2021 → Apr 2025	venous thromboembolism	Sudeep Shivakumar	Completed	No outcome recorded
Phase 3	NCT04673214 Comparator	Dec 2020 → Feb 2021	COVID-19	Gilberto Cruz Arteaga	Completed	No outcome recorded
Phase 3	NCT02722447 Comparator	Jan 2017 → Jun 2019	venous thromboembolism	Walter Ageno	Unknown	No outcome recorded
Phase 3	NCT02387229 Comparator	Mar 2015 → May 2024	atrial fibrillation	Montreal Heart Institute	Terminated	No outcome recorded
Phase 3	NCT01431456 Comparator	Sep 2013 → Oct 2014	venous thromboembolism	Martini Hospital Groningen	Completed	No outcome recorded
Phase 3	NCT01924065 Comparator	Aug 2013 → Aug 2017	atrial fibrillation, stroke disorder	Suleyman Demirel University	Completed	No outcome recorded

Phase 449 trials
Phase 4	NCT06396858 Comparator	Jul 2026 → Aug 2027 expected	ischemic stroke	Brazilian Clinical Research Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT06953726 Comparator	Jun 2026 → Oct 2032 expected	atrial fibrillation	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 4	NCT07352358 Background	Jan 2026 → Jul 2028 expected	cerebral sinovenous thrombosis	Xuanwu Hospital, Beijing	Recruiting	No outcome recorded
Phase 4	NCT06650501 Comparator	Jan 2026 → Jan 2030 expected	infective endocarditis, staphylococcal toxemia, staphylococcus aureus infection	McGill University Health Centre/Research Institute of the McGill University Health Centre	Recruiting	No outcome recorded
Phase 4	NCT06212674 Comparator	Oct 2025 → Oct 2027 expected	atrial fibrillation, ischemic stroke	Medical University of Silesia	Recruiting	No outcome recorded
Phase 4	NCT07243080 Comparator	Oct → Nov 2025 overdue	venous thromboembolism	Mayo Hospital Lahore	Recruiting	No outcome recorded
Phase 4	NCT06862726 Comparator	Dec 2024 → Dec 2025 overdue	atrial fibrillation	Les Laboratoires des Médicaments Stériles	Enrolling by invitation	No outcome recorded
Phase 4	NCT03129490 Comparator	Apr 2023 → Oct 2027 expected	atrial fibrillation, atrial flutter	Herlev and Gentofte Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT03129555 Comparator	Apr 2023 → Mar 2027 expected	pulmonary embolism, venous thromboembolism	Herlev and Gentofte Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT05180773 Comparator	Jul 2022 → Jun 2026 overdue	peripartum cardiomyopathy	Dennis M. McNamara, MD, MS	Recruiting	No outcome recorded
Phase 4	NCT04794569 Comparator	Nov 2021 → Jan 2024	post-thrombotic syndrome, venous thromboembolism	Sunnybrook Health Sciences Centre	Terminated	No outcome recorded
Phase 4	NCT05116995 Comparator	Nov 2021 → Nov 2023	myocardial infarction, thrombotic disease	Nova Scotia Health Authority	Unknown	No outcome recorded
Phase 4	NCT04642430 Comparator	Jul 2021 → Dec 2027 expected	atrial fibrillation	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 4	NCT06986369 Comparator	May 2021 → Aug 2023	coronary atherosclerosis	The University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT04724460 Comparator	Feb 2021 → Sep 2024	neoplasm, venous thromboembolism	Takeshi Morimoto	Completed	No outcome recorded
Phase 4	NCT04757857 Comparator	Sep 2020 → Aug 2022	COVID-19	Hospital Alemão Oswaldo Cruz	Terminated	No outcome recorded
Phase 4	NCT04263038 Comparator	May 2020 → May 2028 expected	hemorrhagic disease, lung disorder, pulmonary embolism, venous thromboembolism	Drahomir Aujesky	Recruiting	No outcome recorded
Phase 4	NCT04250116 Background	Apr 2020 → Apr 2025 overdue	atrial fibrillation	Yonsei University	Active not recruiting	No outcome recorded
Phase 4	NCT04169269 Comparator	Jan → Dec 2020	venous thromboembolism	Florida Orthopaedic Institute	Unknown	No outcome recorded
Phase 4	NCT04023630 Background	Oct 2019 → Sep 2020	acute coronary syndrome, atrial fibrillation	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT03568890 Comparator	Sep 2018 → Aug 2025 overdue	hemorrhagic disease, thrombotic disease, transient ischemic attack	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	Active not recruiting	No outcome recorded
Phase 4	NCT03196349 Comparator	Aug 2018 → May 2019	venous thromboembolism	Duke University	Terminated	No outcome recorded
Phase 4	NCT03463317 Comparator	Feb 2018 → Nov 2024	atrial fibrillation	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 4	NCT03413618 Background	Dec 2017 → Jul 2019	post-thrombotic syndrome, venous thromboembolism	Pirogov Russian National Research Medical University	Completed	No outcome recorded
Phase 4	NCT03266783 Comparator	Dec 2017 → Apr 2025	venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 4	NCT03328832 Comparator	Sep 2017 → Sep 2018	osteoarthritis, knee	Chang Gung Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT03062319 Comparator	Apr 2017 → Jul 2023	atherosclerosis, atrial fibrillation, ischemic stroke	National Hospital Organization Osaka National Hospital	Terminated	No outcome recorded
Phase 4	NCT02974920 Comparator	Jan 2017 → Nov 2022	aortic valve insufficiency, aortic valve stenosis, thrombotic disease	Christian Torp-Pedersen	Unknown	No outcome recorded
Phase 4	NCT02885545 Comparator	Sep 2016 → Mar 2018	chronic kidney disease, stroke disorder	Population Health Research Institute	Withdrawn	No outcome recorded
Phase 4	NCT02559856 Comparator	May 2016 → Nov 2017	venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 4	NCT02723981 Background	Apr 2016 → May 2018	ST-elevation myocardial infarction, intermediate coronary syndrome	IHF GmbH - Institut für Herzinfarktforschung	Withdrawn	No outcome recorded
Phase 4	NCT02701062 Background	Feb 2016 → Apr 2019	atrial fibrillation	AtriCure, Inc.	Completed	No outcome recorded
Phase 4	NCT02168829 Comparator	Jan 2016 → Aug 2025	atrial fibrillation, stroke disorder	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 4	NCT02666157 Comparator	Jan 2016 → Dec 2018	atrial fibrillation	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT02610933 Comparator	Nov 2015 → Jan 2019	calcinosis	Onze Lieve Vrouw Hospital	Completed	No outcome recorded
Phase 4	NCT02549963 Comparator	Oct 2015 → Oct 2017	atrial fibrillation, stroke disorder	Shulin Wu	Unknown	No outcome recorded
Phase 4	NCT02935855 Comparator	Sep 2015 → Apr 2019	diabetes mellitus	University of Pavia	Completed	No outcome recorded
Phase 4	NCT02453802 Comparator	Jun 2015 → May 2016	osteoarthritis, knee	Chang Gung Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT02376010 Comparator	Apr 2015 → Apr 2018	atherosclerosis	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Completed	No outcome recorded
Phase 4	NCT02054936 Comparator	Mar 2014 → Feb 2016	—	University of Michigan	Withdrawn	No outcome recorded
Phase 4	NCT02024230 Comparator	Jan 2014 → Dec 2018	atrial fibrillation, coronary artery disorder, stroke disorder	Fujita Health University	Completed	No outcome recorded
Phase 4	NCT01962545 Background	Nov 2013 → May 2017	atrial fibrillation, coronary artery disorder	Satoshi Shizuta	Completed	No outcome recorded
Phase 4	NCT02331602 Comparator	Jul 2013 → Oct 2015	atrial fibrillation	Yokohama City University Medical Center	Unknown	No outcome recorded
Phase 4	NCT01812200 Comparator	Oct 2012 → May 2013	acute coronary syndrome, atrial fibrillation	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT01747746 Comparator	Oct 2012 → Oct 2014	atrial fibrillation, hemorrhagic disease, stroke disorder, venous thromboembolism	Cook County Health	Completed	No outcome recorded
Phase 4	NCT02458729 Comparator	Aug 2012 → Jul 2014	osteoarthritis, knee	Chang Gung Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT01478282 Comparator	Jan → Dec 2012	hemorrhagic disease, hyperheparinemia, thrombotic disease	Gines Escolar	Unknown	No outcome recorded
Phase 4	NCT02379663 Comparator	Jan 2012 → Jan 2013	avascular necrosis, osteoarthritis, hip	Samsung Medical Center	Completed	No outcome recorded
Phase 4	NCT00559988 Background	Feb 2008 → Jun 2013	arterial occlusion, atrial fibrillation, atrial flutter, stroke disorder	Biotronik, Inc.	Terminated	No outcome recorded

Phase not applicable19 trials
—	NCT07497893 Background	Dec 2026 → Nov 2029 expected	atrial fibrillation	Ewha Womans University Mokdong Hospital	Not yet recruiting	No outcome recorded
—	NCT07616414 Comparator	May → Dec 2026 expected	atrial fibrillation, thrombotic disease	Fu Wai Hospital, Beijing, China	Not yet recruiting	No outcome recorded
—	NCT05993897 Comparator	Aug 2024 → Jun 2025	atrial fibrillation	Aswan University	Completed	No outcome recorded
—	NCT04684212 Comparator	Jun 2024	atrial fibrillation, stroke disorder	Brian O'Neill MD	Withdrawn	No outcome recorded
—	NCT06021808 Comparator	Apr 2024 → Apr 2028 expected	atrial fibrillation	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
—	NCT06055920 Comparator	Nov 2023 → Jul 2026 overdue	pulmonary embolism	Inari Medical	Active not recruiting	No outcome recorded
—	NCT06058130 Comparator	Sep 2023 → Oct 2025	atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
—	NCT05744804 Comparator	Mar → Dec 2023	myocardial infarction	Sohag University	Unknown	No outcome recorded
—	NCT05705076 Comparator	Jan 2023 → Mar 2024	hyperheparinemia	Mansoura University	Unknown	No outcome recorded
—	NCT05701917 Comparator	Jan 2023 → Jun 2026 overdue	post-thrombotic syndrome, venous thromboembolism	Inari Medical	Recruiting	No outcome recorded
—	NCT05472766 Comparator	Nov 2022 → Mar 2024	atrial fibrillation	Sunnybrook Health Sciences Centre	Terminated	No outcome recorded
—	NCT05622500 Background	Sep 2022 → Apr 2025	chronic venous insufficiency, post-thrombotic syndrome	Imperial College London	Terminated	No outcome recorded
—	NCT06449469 Background	May 2021 → Apr 2026 overdue	aortic valve stenosis	Rigshospitalet, Denmark	Active not recruiting	No outcome recorded
—	NCT03465735 Background	Jan 2017 → Aug 2019	venous thromboembolism	Mayo Clinic	Terminated	No outcome recorded
—	NCT02744092 Comparator	Dec 2016 → Oct 2020	cancer, pulmonary embolism, thrombotic disease, venous thromboembolism	Alliance Foundation Trials, LLC.	Completed	No outcome recorded
—	NCT02704598 Comparator	Mar 2016 → Dec 2018	venous thromboembolism	Hospital do Servidor Publico Estadual	Unknown	No outcome recorded
—	NCT01999179 Background	Jun 2014 → Apr 2019	neoplasm, venous thromboembolism	Medical College of Wisconsin	Completed	No outcome recorded
—	NCT03201367 Comparator	May 2014 → Aug 2016	portal vein thrombosis	Zagazig University	Completed	No outcome recorded
—	NCT02422602 Comparator	Nov 2013 → May 2015	atrial fibrillation	University Hospital, Montpellier	Completed	No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 394 sources stand behind the page.

Field	Value	Cited text
Known as	Rivaroxaban	“AF patients with a CHA2DS2-VASc score >2 and no previous history of overt coronary disease, severe peripheral arterial disease (PAD) or major stroke will be registered and...” PMID 27558002 ↗ Aug 2016 388 “Patients will be chronically treated with NOAC including apixaban (2x5 mg or 2x2.5 mg depending on the dose reduction regimen) or dabigatran (2x150 mg or 2x110 mg depending on...” NCT06212674 ↗ “DOACs (eg Apixaban, dabigatran, edoxaban and rivaroxaban) are recommended by The National Institute for Health and Care Excellence (NICE) for those over 65 with AF and a...” NCT06322953 ↗ “NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice...” NCT01962545 ↗ “edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or...” NCT03968393 ↗ “Century Clot-guided rivaroxaban prophylactic therapy (2.5 mg twice daily, if the hypercoagulable state, defined as CR ≥24) in combination with standard DAPT could reduce LVT...” NCT06013020 ↗ “For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral...” NCT06021808 ↗ “For those randomized to group B (NOAC group), patients will be treated using a registered NOAC (rivaroxaban, apixaban or dabigatran, but preferentionally apixaban) at the dose...” NCT02426944 ↗ “The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month...” NCT03804697 ↗ “Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then...” NCT02331095 ↗ “Non-vitamin K antagonist oral anticoagulant therapy (e.g., apixaban, rivaroxaban, dabigatran, or edoxaban) administered according to approved labeling and guideline-recommended dosing.” NCT07497893 ↗ “The PK sub-study is being conducted to assess the blood pharmacokinetics of the three drugs (Sirolimus, Rivaroxaban, Argatroban) eluted from the DESyne BDS Plus after implantation.” NCT05033964 ↗ “Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles.” NCT06615596 ↗ “Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.” NCT07583784 ↗ “Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) or rivaroxaban 20mg once daily (15mg once daily if meets dose-reduction criteria) for 2 years” NCT04437654 ↗ “Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization.” NCT04250116 ↗ “Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.” NCT05622500 ↗ “This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.” NCT06913595 ↗ “Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.” NCT06055920 ↗ “The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)” NCT03285438 ↗ “Patients who are over 20 years old, have non-valvular atrial fibrillation, and are taking rivaroxaban, apixaban, or edoxaban (active ingredients)” NCT05801068 ↗ “Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.” NCT05198960 ↗ “DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care” NCT05825573 ↗ “Administration of approved DOACs (e.g., apixaban, rivaroxaban, edoxaban, or dabigatran) at standard stroke prevention dosages.” NCT07609654 ↗ “For rivaroxaban: 10mg once daily for patients with standard 15mg dose, 15mg once daily for patients with standard 20mg dose” NCT07616414 ↗ “Low-molecular-weight heparin bridging to warfarin 3 mg/day, rivaroxaban 10-20 mg/day or dabigatran 110-150 mg twice daily.” NCT07352358 ↗ “Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation.” NCT02998905 ↗ “Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.” NCT03642509 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females.” NCT05993897 ↗ “Rivaroxaban 20mg once daily or 15mg once daily / Dabigatran 110mg twice daily or 150mg twice daily” NCT06058130 ↗ “Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)” NCT05387954 ↗ “using the direct oral anticoagulant Rivaroxaban (brand name: Xarelto) at the recommended dose.” NCT06611319 ↗ “Post-procedural oral anticoagulation is transitioned to rivaroxaban 20 mg once daily (QD).” NCT07032025 ↗ “choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice” NCT04700826 ↗ “Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP” NCT05472766 ↗ “any approved direct oral anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran)” NCT04045665 ↗ “direct oral anticoagulant treatment (apixaban, rivaroxaban, dabigatran, or edoxaban)” NCT01999179 ↗ “Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.” NCT06057467 ↗ “OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA” NCT00559988 ↗ “Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban” NCT06401616 ↗ “Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)” NCT05006287 ↗ “Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban” NCT01627665 ↗ “Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily” NCT04619927 ↗ “Rivaroxaban was given for minimum 4 weeks depending on D dimer levels” NCT04935515 ↗ “warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage” NCT01924065 ↗ “New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban” NCT02701062 ↗ “to receive either an 18-month or a 6-month rivaroxaban treatment” PMID 39556015 ↗ Nov 2024 “Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days” NCT04673214 ↗ “vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od” NCT02885545 ↗ “warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban” NCT03062319 ↗ “Rivaroxaban: 20 mg once a day or 15 mg once a day” NCT06862726 ↗ “dabigatran, apixaban, edoxaban, rivaroxaban” NCT03759938 ↗ “group B : Rivaroxaban 10 mg plus placebo” NCT05705076 ↗ “Apixaban Dabigatran Edoxaban Rivaroxaban” NCT05292846 ↗ “Xarelto (Rivaroxaban, BAY59-7939)” NCT00973323 ↗ “Intervention Arm: Rivaroxaban” NCT07456085 ↗ “Rivaroxaban (Xarelto)” NCT07011095 ↗ “Rivaroxaban (Xarelto)” NCT03465735 ↗ “Rivaroxaban (Xarelto)” NCT01706146 ↗ “RIVAROXABAN 40 mg” NCT01627665 ↗ “Rivaroxaban 2.5mg” NCT05418803 ↗ “Rivaroxaban” NCT05300555 ↗ “Rivaroxaban” NCT02666742 ↗ NCT05449327 ↗ NCT06901466 ↗ NCT02128841 ↗ NCT07468448 ↗ NCT04970381 ↗ NCT07270263 ↗ NCT02723981 ↗ NCT03566303 ↗ NCT03996772 ↗ NCT07523347 ↗ NCT05546957 ↗ NCT05546320 ↗ NCT06978439 ↗ NCT03792152 ↗ NCT07318610 ↗ NCT02935855 ↗ NCT04218656 ↗ NCT03605433 ↗ NCT02846532 ↗ NCT02123524 ↗ NCT03282643 ↗ NCT02555878 ↗ NCT04256525 ↗ NCT07511257 ↗ NCT06314763 ↗ NCT04767776 ↗ NCT06961630 ↗ NCT06396858 ↗ NCT02556203 ↗ NCT04258488 ↗ NCT03148457 ↗ NCT02506985 ↗ NCT03193502 ↗ NCT03083704 ↗ NCT03684564 ↗ NCT05735639 ↗ NCT06065592 ↗ NCT04967573 ↗ NCT02810704 ↗ NCT01094886 ↗ NCT03363035 ↗ NCT02085824 ↗ NCT00395772 ↗ NCT03568890 ↗ NCT03172910 ↗ NCT01853800 ↗ NCT01989845 ↗ NCT02024230 ↗ NCT07202897 ↗ NCT06517563 ↗ NCT01499953 ↗ NCT04263038 ↗ NCT02627053 ↗ NCT05515120 ↗ NCT05077683 ↗ NCT03764241 ↗ NCT03178864 ↗ NCT04757857 ↗ NCT00786422 ↗ NCT05705089 ↗ NCT04755283 ↗ NCT01629381 ↗ NCT04397289 ↗ NCT01464450 ↗ NCT03273322 ↗ NCT05033314 ↗ NCT04838808 ↗ NCT05047172 ↗ NCT02497716 ↗ NCT05180773 ↗ NCT06925698 ↗ NCT06449469 ↗ NCT05035277 ↗ NCT02072668 ↗ NCT05701917 ↗ NCT01379300 ↗ NCT02157272 ↗ NCT00809965 ↗ NCT05152420 ↗ NCT07246005 ↗ NCT03673605 ↗ NCT01400646 ↗ NCT06531122 ↗ NCT05718531 ↗ NCT06650501 ↗ NCT01986192 ↗ NCT02722447 ↗ NCT02704598 ↗ NCT05700266 ↗ NCT03428373 ↗ NCT07699796 ↗ NCT02401594 ↗ NCT02438098 ↗ NCT02168829 ↗ NCT01708850 ↗ NCT01747746 ↗ NCT02334254 ↗ NCT04169269 ↗ NCT05491460 ↗ NCT04853719 ↗ NCT04273516 ↗ NCT03969953 ↗ NCT05487950 ↗ NCT04351724 ↗ NCT03702582 ↗ NCT04990791 ↗ NCT02042534 ↗ NCT02303795 ↗ NCT03005444 ↗ NCT03055026 ↗ NCT05892042 ↗ NCT01877915 ↗ NCT07243080 ↗ NCT02260622 ↗ NCT05300555 ↗ NCT05303818 ↗ NCT02559856 ↗ NCT03201367 ↗ NCT03153150 ↗ NCT03129490 ↗ NCT06953726 ↗ NCT03328832 ↗ NCT01309438 ↗ NCT03331484 ↗ NCT05308030 ↗ NCT06019741 ↗ NCT06986369 ↗ NCT03463317 ↗ NCT02974920 ↗ NCT04284839 ↗ NCT03129555 ↗ NCT01839357 ↗ NCT03139487 ↗ NCT05088928 ↗ NCT06551402 ↗ NCT05638867 ↗ NCT03578146 ↗ NCT04727021 ↗ NCT01442792 ↗ NCT00973245 ↗ NCT00329628 ↗ NCT03277001 ↗ NCT06831474 ↗ NCT06444178 ↗ NCT01656330 ↗ NCT04874428 ↗ NCT04023630 ↗ NCT04135677 ↗ NCT04640181 ↗ NCT02379663 ↗ NCT04642430 ↗ NCT06187311 ↗ NCT02583191 ↗ NCT05775965 ↗ NCT06108414 ↗ NCT04805710 ↗ NCT01431456 ↗ NCT05116995 ↗ NCT05643651 ↗ NCT05009862 ↗ NCT02234843 ↗ NCT00396786 ↗ NCT03799822 ↗ NCT04994223 ↗ NCT05210725 ↗ NCT00332020 ↗ NCT02664155 ↗ NCT02666157 ↗ NCT05920343 ↗ NCT02116036 ↗ NCT04569279 ↗ NCT01210755 ↗ NCT06689241 ↗ NCT00494871 ↗ NCT01954238 ↗ NCT01478282 ↗ NCT01674647 ↗ NCT05744804 ↗ NCT02453802 ↗ NCT01729871 ↗ NCT01344954 ↗ NCT04720092 ↗ NCT06103266 ↗ NCT04180436 ↗ NCT02549963 ↗ NCT04394377 ↗ NCT01675076 ↗ NCT04333407 ↗ NCT06370273 ↗ NCT02271399 ↗ NCT04970576 ↗ NCT00839826 ↗ NCT04715295 ↗ NCT04059679 ↗ NCT03864406 ↗ NCT02066662 ↗ NCT02642419 ↗ NCT00403767 ↗ NCT06476301 ↗ NCT07312851 ↗ NCT00398905 ↗ NCT00362232 ↗ NCT04486859 ↗ NCT01776424 ↗ NCT02058199 ↗ NCT00361894 ↗ NCT01812200 ↗ NCT02561923 ↗ NCT06195540 ↗ NCT00562289 ↗ NCT01145859 ↗ NCT02331602 ↗ NCT02657512 ↗ NCT06780462 ↗ NCT00779064 ↗ NCT06196918 ↗ NCT00839163 ↗ NCT04006288 ↗ NCT04662684 ↗ NCT01205932 ↗ NCT02744092 ↗ NCT03718429 ↗ NCT02643212 ↗ NCT02970773 ↗ NCT03786757 ↗ NCT04416048 ↗ NCT07602062 ↗ NCT02833948 ↗ NCT00402597 ↗ NCT01923818 ↗ NCT05353140 ↗ NCT02289703 ↗ NCT02832947 ↗ NCT04508023 ↗ NCT02293395 ↗ NCT04075240 ↗ NCT02746185 ↗ NCT02926170 ↗ NCT05233124 ↗ NCT02313909 ↗ NCT04142125 ↗ NCT04324463 ↗ NCT00440193 ↗ NCT02376010 ↗ NCT06873321 ↗ NCT03490994 ↗ NCT02504216 ↗ NCT03413618 ↗ NCT05410275 ↗ NCT00571649 ↗ NCT06965998 ↗ NCT04999176 ↗ NCT00402467 ↗ NCT03926780 ↗ NCT01598168 ↗ NCT01206972 ↗ NCT04504032 ↗ NCT03181386 ↗ NCT06580223 ↗ NCT03506815 ↗ NCT03749057 ↗ NCT02832531 ↗ NCT03796377 ↗ NCT02054936 ↗ NCT07613840 ↗ NCT03926156 ↗ NCT04694248 ↗ NCT04309240 ↗ NCT06372483 ↗ NCT06145269 ↗ NCT04794569 ↗ NCT05797376 ↗ NCT02584660 ↗ NCT02894307 ↗ NCT02486445 ↗ NCT03310021 ↗ NCT04066764 ↗ NCT05128591 ↗ NCT05973188 ↗ NCT03630055 ↗ NCT07404436 ↗ NCT04002011 ↗ NCT02161965 ↗ NCT03196349 ↗ NCT04073316 ↗ NCT07228663 ↗ NCT06216769 ↗ NCT00439777 ↗ NCT01507051 ↗ NCT02564718 ↗ NCT01516840 ↗ NCT07618988 ↗ NCT05573958 ↗ NCT02111564 ↗ NCT06220123 ↗ NCT07195812 ↗ NCT03266783 ↗ NCT05723510 ↗ NCT05750758 ↗ NCT04067505 ↗ NCT02309411 ↗ NCT03522259 ↗ NCT06812455 ↗ NCT02458729 ↗ NCT05960721 ↗ NCT01720108 ↗ NCT01516814 ↗ NCT02047006 ↗ NCT02610933 ↗ NCT02164578 ↗ NCT00439725 ↗ NCT02829957 ↗ NCT03299296 ↗ NCT07077954 ↗ NCT02387229 ↗ NCT05671276 ↗ NCT05794399 ↗ NCT04684212 ↗ NCT03747081 ↗ NCT02367027 ↗ NCT05029063 ↗ NCT02832544 ↗ NCT01830543 ↗ NCT03775746 ↗ NCT01684423 ↗
Known as	BAY59-7939	“Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism” NCT00403767 ↗ 42 “One promising therapeutic option is rivaroxaban (BAY 59-7939, Rivaroxaban), an orally administered direct factor Xa inhibitor” NCT02438098 ↗ “Two Strategies of Rivaroxaban [JNJ39039039; BAY-59-7939] and One of Oral Vitamin K Antagonist” NCT01830543 ↗ “Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.” NCT00362232 ↗ “Drug: Xarelto (Rivaroxaban, BAY59-7939)” NCT00973245 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01507051 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT02504216 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01442792 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01853800 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02556203 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00786422 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02367027 ↗ “Xarelto (Rivaroxaban, BAY59-7939)” NCT00973323 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02234843 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT04720092 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01776424 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01145859 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00439777 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02564718 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01684423 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01516814 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02309411 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00439725 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01516840 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00571649 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02313909 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00440193 ↗ “Xarelto (Rivaroxaban, BAY59-7939)” NCT00839163 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00398905 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01674647 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00494871 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00396786 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01839357 ↗ “Xarelto (Rivaroxaban, BAY59-7939)” NCT00395772 ↗ “Rivaroxaban (Xarelto, BAY59-7939” NCT02497716 ↗ “Drug: Rivaroxaban (BAY59-7939)” NCT00332020 ↗ “Drug: Rivaroxaban (BAY59-7939)” NCT01206972 ↗ “Rivaroxaban (BAY59-7939)” NCT00329628 ↗ “Rivaroxaban (BAY59-7939)” NCT00402467 ↗ “Rivaroxaban (BAY59-7939)” NCT01205932 ↗ “Rivaroxaban (BAY59-7939)” NCT00779064 ↗ “Rivaroxaban (BAY59-7939)” NCT00361894 ↗ NCT02064439 ↗
Known as	Direct Oral Anticoagulant (DOAC)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05498428 ↗
Known as	JNJ39039039	“Two Strategies of Rivaroxaban [JNJ39039039; BAY-59-7939] and One of Oral Vitamin K Antagonist” NCT01830543 ↗
Known as	Rivaroxaban (Xarelto)	“Rivaroxaban (Xarelto)” NCT07011095 ↗ 2 “Rivaroxaban (Xarelto)” NCT03465735 ↗ “Rivaroxaban (Xarelto)” NCT01706146 ↗
Known as	Rivaroxaban accord	ChEMBL registry synonym — accepted as the source's own label CHEMBL198362 ↗
Known as	Rivaroxaban viatris (previously rivaroxaban mylan)	ChEMBL registry synonym — accepted as the source's own label CHEMBL198362 ↗
Known as	Rivaroxabana	“Xarelto 15 mg Rivaroxabana 15 mg” NCT05515120 ↗
Known as	Rovaltro	“Rivaroxaban (Rovaltro®) is a novel oral anticoagulant” NCT04569279 ↗
Known as	Xarelto	“Thromboprophylactic regimens Aspirin®(acetylsalicylic acid, AA, Bayer) 300mg/day or Xarelto® (rivaroxaban, factor Xa-inhibitor, Bayer) 10mg/day will be randomly(according to...” NCT02271399 ↗ 48 “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗ “A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19” NCT04504032 ↗ “Blood concentrations of rivaroxaban (Xarelto, Titusville, New Jersey) at 4 weeks were undetectable in 21% patients from Eastern Europe” PMID 33549557 ↗ Feb 2021 “Single administration of oral rivaroxaban in the form of Xarelto® 10mg tablets (Bayer Schering Pharma, Berlin, Germany).” NCT02970773 ↗ “Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)” NCT03148457 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto).” NCT06953726 ↗ “Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.” NCT00362232 ↗ “a new blood thinner called rivaroxaban (Xarelto) can be used to treat HIT” NCT01598168 ↗ “Drug: Xarelto (Rivaroxaban, BAY59-7939)” NCT00973245 ↗ “Rivaroxaban 10 MG Oral Tablet [Xarelto]” NCT04994223 ↗ “Rivaroxaban 10 MG Oral Tablet [Xarelto]” NCT03522259 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01507051 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT02504216 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01442792 ↗ “Drug: Rivaroxaban (Xarelto, BAY59-7939)” NCT01853800 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02556203 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00786422 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02234843 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT04720092 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01776424 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01145859 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02367027 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02309411 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02564718 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01684423 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00439725 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01516814 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00439777 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01516840 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00571649 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00440193 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT02313909 ↗ “Xarelto (Rivaroxaban, BAY59-7939)” NCT00839163 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00398905 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01674647 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00494871 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT01839357 ↗ “Rivaroxaban (Xarelto, BAY59-7939)” NCT00396786 ↗ “Xarelto (Rivaroxaban, BAY59-7939)” NCT00395772 ↗ “Rivaroxaban (Xarelto, BAY59-7939” NCT02497716 ↗ “Rivaroxaban 2.5 MG [Xarelto]” NCT04838808 ↗ “Rivaroxaban 2.5 MG [Xarelto]” NCT05077683 ↗ “Rivaroxaban (Xarelto)” NCT02054936 ↗ “Rivaroxaban (Xarelto)” NCT06978439 ↗ NCT02555111 ↗ NCT02422602 ↗ NCT00973323 ↗
Known as	Xarelto is the brand name for rivaroxaban	“Xarelto is the brand name for rivaroxaban” NCT01478282 ↗
Action	Inhibit	“an oral direct inhibitor of factor Xa” PMID 18579811 ↗ Jun 2008
Modality	Other / unclassified	“direct oral anticoagulant” NCT04794569 ↗
Route	Oral	“10 mg of oral rivaroxaban once daily” PMID 18579811 ↗ Jun 2008
Target	F10	“the direct factor Xa inhibitor rivaroxaban” NCT01812200 ↗